Lunai Bioworks Acquires BBB Delivery Technology and CNS Alzheimer’s Drug Assets from the Clemann Group

AbbVie Completes $1.4B Acquisition of Aliada Therapeutics

December 11, 2024

Biotechnology

AbbVie completed its $1.4 billion cash acquisition of RA Capital Management portfolio company Aliada Therapeutics. The deal adds ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody in Phase 1 for Alzheimer’s disease, and Aliada’s blood-brain barrier (BBB)-crossing MODEL delivery platform to AbbVie’s neuroscience pipeline.

Lantheus Holdings Acquires Cerveau Technologies

February 6, 2023

Pharmaceuticals

Lantheus Holdings, Inc. acquired Knoxville-based Cerveau Technologies, Inc., gaining MK-6240, a clinical-stage F-18 PET imaging agent that targets Tau tangles in Alzheimer's disease. The stock purchase includes upfront and potential milestone payments plus royalty obligations and will expand Lantheus' radiopharmaceutical diagnostic imaging pipeline and research collaborations.

Lantheus Acquires Meilleur Technologies (NAV-4694)

July 15, 2024

Pharmaceuticals

Lantheus Holdings, Inc. announced the acquisition of Meilleur Technologies, Inc., giving Lantheus worldwide exclusive rights to NAV-4694 (F18-flutafuranol), a Phase 3 ß-amyloid PET imaging agent for Alzheimer’s disease. The deal includes an upfront payment plus potential development/commercial milestones and royalties, and the sellers will provide transition and clinical development services following closing.

Boston Scientific to Acquire Nalu Medical, Inc.

October 17, 2025

Healthcare Services

Boston Scientific entered into a definitive agreement to acquire Nalu Medical, Inc., a privately held medical technology company focused on minimally invasive chronic pain neuromodulation. The deal includes an upfront cash payment of approximately $533 million for the remaining equity not already owned by Boston Scientific, with Boston Scientific expecting closing in the first half of 2026.

Dr. Glenn Haifer and Ampersand Capital Partners Acquire Luina Bio, Rebrand as AcuraBio

August 30, 2022

Biotechnology

Biotech investor Dr. Glenn Haifer and healthcare private equity firm Ampersand Capital Partners have acquired Australian CDMO Luina Bio and rebranded it as AcuraBio. The investors plan to inject capital to expand production capacity, broaden service offerings and build AcuraBio into a leading APAC biologics contract development and manufacturing organization.

Asahi Kasei Medical to Acquire Bionova Scientific

April 14, 2022

Healthcare Services

Asahi Kasei Medical, through a U.S. subsidiary, has agreed to wholly acquire Bionova Scientific, LLC, a U.S.-based biopharmaceutical CDMO providing contract process development and GMP-compliant contract manufacturing services. The acquisition will add CDMO capabilities to Asahi Kasei Medical’s existing bioprocess business and broaden know-how-driven services for next-generation antibody drugs.